Search

Find exactly what you’re looking for.
Search

Service
Location
Showing 21-27 of 27 results

Opportunity Zones offer potential benefits for your clients, but it's crucial to distinguish between good and bad investments. Delve into the intricacies of the Opportunity Zone program, compliance and reporting obligations involved in maintaining these investments, and tax benefits that are...

Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...

Saul Ewing LLP, a full-service law firm with attorneys in 16 offices, today announced that The Bond Buyer recognized the Firm’s Public Finance Practice on its Northeast Midyear Review lists of the Top Five Bond Counsel for 2022. The Firm earned a number one ranking in Delaware and a number four...

​On August 4th, the Pennsylvania Commonwealth Court (the “Court”) issued its decision in Ursinus College v. Prevailing Wage Appeals Board. The Court reversed a decision by the Prevailing Wage Appeals Board (the “Board”) in which the Board found that a construction project financed with tax-exempt...

(Washington, DC, July 21, 2021) – Earl Adams, Jr., co-chair of the firm’s Regulatory, Compliance and Government practice, and Managing Partner of the firm’s Washington, D.C. office, has been appointed by President Biden to serve as Chief Counsel to the Federal Motor Carrier Safety Administration (...

To Correct, or to Let Stand? When high-profile figures lie about their academic records, the institutions they attended must perform a delicate balancing act between protecting their privacy and telling the truth. by Liam Knox “The hands of the institution are tied in a lot of ways from getting...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us